查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1950423

主动脉和周边血管介入器械市场（按器械类型、技术、植入材料、应用和最终用户划分），全球预测，2026-2032年

Aortic & Peripheral Vascular Interventional Devices Market by Device Type, Technology, Implant Material, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，主动脉和周边血管介入器材市场价值将达到 87.8 亿美元，到 2026 年将成长至 93.5 亿美元，到 2032 年将达到 134.5 亿美元，年复合成长率为 6.27%。

关键市场统计数据
基准年 2025 87.8亿美元
预计年份：2026年 93.5亿美元
预测年份 2032 134.5亿美元
复合年增长率 (%) 6.27%

这是一份以临床为依据、重点突出的概述，阐述了影响主动脉和周边血管器械领域的程序优先事项、相关人员的压力以及战略要务。

主动脉和周边介入器材市场已进入一个以快速临床创新、不断变化的手术环境以及对器械耐用性和长期疗效日益严格的审查为特征的阶段。临床医师越来越重视那些既易于实施又能针对特异性病变改善疗效的技术，而医疗系统则要求在手术全期资源利用率和患者吞吐量方面取得显着改善。同时，监管路径和报销动态也在同步发展，影响企业如何优先考虑研发、上市后证据的收集以及市场准入顺序。

临床创新、材料科学进步、手术流程向门诊转移以及供应链重组，正在如何重塑血管器械生态系统的策略重点？

近年来，主动脉和周边血管介入治疗领域发生了一系列变革性变化，重新定义了竞争优势，而且这些变化仍在加速发展。首先，临床实践正朝着微创技术和先进的血管内介入方法发展，从而缩短了住院时间，并扩大了传统上只能接受保守治疗的患者范围。器械小型化和输送系统的改进减少了手术创伤，使得门诊和混合手术成为可能，随着手术方式的转变，也创造了商业性机会。

评估2025年关税对经济、供应链和临床的多层次影响，并考虑相关人员如何积极应对。

2025年宣布的一系列关税措施的累积影响，给主动脉和周边血管护理领域的製造商、医疗服务提供者和采购机构带来了复杂的挑战。进口原料和成品器械关税的增加，直接推高了依赖全球孤立供应链的製造商的投入成本。这些压力迫使多家公司重新评估其定价策略，尽可能承担成本以维持市场成长势头，并加快供应链的长期调整以降低未来风险。

制定有针对性的产品和商业策略，采用以细分市场主导的详细观点，将应用、设备设计、技术、材料科学和最终用户画像连结起来。

细分市场分析能够深入了解主动脉和周边血管器械市场中临床需求与技术创新之间的交集。在考虑应用场景时，主动脉和周边应用场景的差异决定了器械的尺寸、输送系统机制和手术流程，进而影响临床训练需求和设备需求。按器械类型划分，市场涵盖：切割球囊（包括切割球囊、药物释放型血管成形术用气球和标准球囊）；栓塞保护装置（按远端保护和近端保护区分）；用于腹主动脉和胸主动脉的血管内血管支架；球囊扩张式或自扩张式外周支架；以及血栓除去装置（包括机械血栓切除术和抽血栓切除术）。这些器械层面的差异驱动着医院和门诊的研发重点、监管证据的累积以及库存策略。

美洲、欧洲、中东和非洲以及亚太地区的区域管理体制、报销模式和手术流程采用模式将如何决定差异化的商业化和生产选择？

区域趋势正在影响主动脉和周边血管领域的创新发展、监管策略和商业性执行。在美洲，临床应用往往受到奖励手术效率和疗效的报销机制的驱动，这为那些能够缩短住院时间和提高长期通畅性的技术创造了有利环境。这一趋势促使製造商投资于可靠的临床证据，并儘早与大规模综合医疗网络合作，以获得优先供应商地位和基于销售的合约。

主导情报的竞争态势评估、创新方向以及决定医疗器材平台和临床细分市场市场领导地位的策略行动

主动脉和周边血管器材领域的竞争格局由全球平台领导者、专业创新者和垂直整合型竞争对手组成，它们在设计、材料和临床证据方面竞争。拥有丰富产品系列的老字型大小企业利用规模经济优势，为长期临床试验提供资金筹措，并维持多元化的製造地，从而提供吸引大型医疗系统和集团采购组织的端到端外科解决方案。专业公司则专注于特定器械领域，例如药物释放型球囊、先进的血管支架设计和改良的血栓切除系统。在这些领域，临床差异化和针对性的证据推动了关键意见领袖（KOL）对产品的快速接受。

製造商和供应商应采取实际有效、影响深远的策略行动和商业性转型，以确保韧性、加速产品普及并展现长期价值。

行业领导者必须采取一系列战术性和策略倡议，以维持成长并应对快速变化的临床和商业环境。製造商应优先进行产品组合优化，专注于高影响力医疗器材子集，并选择性地投资于能够带来可衡量临床优势的药物涂层和材料科学升级。同时，透过对多家供应商进行资格认证、寻求近岸生产方案以及发展模组化生产能力来加强供应链多元化，可以降低贸易中断和关税波动带来的风险。

该分析基于严格的混合方法研究方法，结合了主要临床访谈、次要证据综合、分割映射和检验程序。

本执行摘要的研究采用了系统性的一手和二手调查方法相结合的方式，以确保其可靠性和相关性。一手研究包括对介入性心臟病专家、血管外科医生、采购主管和医疗设备工程师进行结构化访谈，以收集关于临床效用、器械选择标准和运营限制的第一手资讯。此外，还与器材创新者和医疗系统领导者举行了咨询小组简报会，检验新出现的主题并测试商业场景。

简洁地概括了关键的临床、商业性和营运问题，为相关人员应对不断变化的挑战提供协作方向，并确保患者照护的永续进步。

总而言之，主动脉和周边介入器材市场格局正受到多种因素的重塑，包括：临床上对微创和持久治疗方法的偏好；材料和药物输送技术的创新正在改变再次介入的风险状况；以及商业性模式向基于价值的采购和具有韧性的供应链转变。这些因素相互作用，影响所有器械类型，从血管成形球囊和栓塞保护系统到复杂的血管支架和血栓切除平台，并且会因技术、植入材料和最终用户环境的不同而有所差异。因此，技术差异化必须与可证明的营运和经济价值结合，才能确保器械的持续应用。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 主动脉及週边血管介入器材市场（依器械类型划分）

  • 血管成形球囊
    • 切割球囊
    • 药物释放型球囊
    • 标准气球
  • 栓塞保护装置
    • 远端保护
    • 近端保护
  • 血管内支架血管支架
    • 腹主动脉
    • 胸主动脉
  • 週边血管支架
    • 气球膨胀类型
    • 自膨胀
  • 血栓清除装置
    • 机械血栓切除术
    • 抽吸血栓清除法

9. 主动脉及週边介入器材市场（依技术划分）

  • 裸金属
  • 药物包衣型

10. 主动脉及週边血管介入器材市场（依植入材料划分）

  • 钴铬
  • 镍钛诺
  • 不銹钢

11. 主动脉及週边血管介入器材市场（依应用领域划分）

  • 主动脉
  • 外围

12. 主动脉和周边血管介入器材市场（依最终用户划分）

  • 门诊手术中心
  • 医院
  • 专科诊所

13. 各地区主动脉及週边血管介入器材市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 主动脉和周边介入器材市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国主动脉及週边血管介入器材市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国主动脉及週边介入器材市场

17. 中国：主动脉与週边血管介入器材市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cardinal Health
  • Cook Medical LLC
  • Getinge AB
  • Johnson & Johnson
  • LivaNova PLC
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • MicroPort Endovascular MedTech
  • Penumbra, Inc.
  • Terumo Corporation
  • WL Gore & Associates, Inc.
Product Code: MRR-4F7A6D4FD855

The Aortic & Peripheral Vascular Interventional Devices Market was valued at USD 8.78 billion in 2025 and is projected to grow to USD 9.35 billion in 2026, with a CAGR of 6.27%, reaching USD 13.45 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.78 billion
Estimated Year [2026] USD 9.35 billion
Forecast Year [2032] USD 13.45 billion
CAGR (%) 6.27%

A focused, clinically grounded overview that situates procedural priorities, stakeholder pressures, and strategic imperatives shaping the aortic and peripheral vascular device arena

The aortic and peripheral vascular interventional device landscape has entered a period defined by rapid clinical innovation, shifting procedural settings, and heightened scrutiny on device durability and long-term outcomes. Clinicians increasingly prioritize technologies that combine ease of delivery with improved lesion-specific performance, while health systems demand demonstrable improvements in perioperative resource utilization and patient throughput. At the same time, regulatory pathways and reimbursement dynamics are evolving in parallel, shaping how companies prioritize development, post-market evidence generation, and market entry sequencing.

This executive summary synthesizes contemporary clinical trends, competitive behaviors, and strategic imperatives facing manufacturers, providers, and purchasers. It highlights how therapy selection for aortic compared with peripheral applications is being influenced by device design, material science, and adjunctive technologies. The summary also frames why decisions by hospitals, ambulatory surgery centers, and specialty clinics now extend beyond clinical efficacy to include procedural efficiency, inventory management, and lifecycle costs. By situating clinical drivers alongside commercial and regulatory realities, the introduction sets the foundation for deeper analysis and actionable recommendations contained in the subsequent sections.

How clinical innovation, material science advances, procedural migration to outpatient settings, and supply chain reconfiguration are reshaping strategic priorities across the vascular device ecosystem

Over recent years, multiple transformative shifts have redefined competitive advantage in aortic and peripheral vascular interventions, and these shifts continue to accelerate. First, the clinical community is converging on less invasive techniques and refined endovascular approaches that reduce length of stay and broaden candidacy among patients previously managed conservatively. Device miniaturization and delivery-system refinement have decreased access trauma and facilitated treatment in outpatient and hybrid settings, creating commercial opportunities tied to procedural migration.

Second, material innovation has become a decisive differentiator. Adoption of nitinol for its superelastic properties, cobalt chromium for radial strength, and stainless steel for cost-effective scaffolding has allowed manufacturers to tailor performance across aortic and peripheral indications. Concurrently, drug-coating technologies are influencing restenosis management strategies, fostering new combinations of scaffold design and pharmacologic control that change follow-up pathways and reintervention rates. Third, the integration of digital imaging, procedural guidance systems, and real-time analytics is improving device placement accuracy and reducing operator variability, while creating data-rich evidence streams for payers and regulators.

Fourth, the commercial environment has shifted toward outcome- and value-based contracting models. Payers and large hospital systems increasingly seek devices and care pathways that demonstrably lower total cost of care across episodes, incentivizing manufacturers to demonstrate longitudinal benefits. Finally, supply chain resilience and regional manufacturing strategies have emerged as strategic priorities following episodic disruptions, driving investments in dual-sourcing, inventory optimization, and near-shoring. Together, these shifts are reshaping R&D priorities, go-to-market strategies, and partnership models across the ecosystem.

Assessing the layered economic, supply chain, and clinical adoption consequences that followed tariff measures introduced in 2025 and how stakeholders can respond proactively

The cumulative impact of tariff actions announced in 2025 has created complex headwinds for manufacturers, providers, and procurement organizations engaged in aortic and peripheral vascular therapies. Tariff-induced cost escalation for imported raw materials and finished devices has directly increased input costs for manufacturers that rely on globalized supply chains. These pressures have compelled several companies to reassess pricing strategies, absorb costs where possible to protect adoption momentum, and accelerate longer-term supply chain adjustments to mitigate future exposure.

Beyond immediate cost implications, tariffs have influenced strategic decisions related to manufacturing footprint and supplier selection. Companies with flexible manufacturing models and multi-jurisdictional production have been better positioned to shield end users from acute price shocks. In contrast, single-source supply models and heavy dependence on components produced in tariff-affected jurisdictions have necessitated rapid supplier diversification or investments in alternative materials and processes. For hospitals and ambulatory surgery centers, the cumulative effect has been constrained purchasing flexibility and an increased emphasis on product rationalization to manage capital expenditure and inventory carrying costs.

Tariffs have also indirectly affected clinical adoption patterns. Where increased costs have coincided with marginal clinical advantage between competing technologies, procurement committees have favored cost-stable alternatives or deferred elective procedures. Conversely, technologies that reduce lengths of stay, reintervention, or downstream resource utilization have preserved purchasing preference despite higher upfront pricing, as their value proposition aligns with institutional cost-containment goals. Finally, policy uncertainty created by tariff shifts has amplified the need for scenario-based planning across commercial, clinical, and regulatory functions, encouraging stakeholders to model multiple procurement and reimbursement outcomes and to prioritize contractual flexibility and supply chain visibility.

A detailed segmentation-driven perspective that connects application, device design, technology, material science, and end-user profiles to inform targeted product and commercial strategies

Segmentation drives a nuanced understanding of where clinical demand and innovation converge within the aortic and peripheral vascular device landscape. When considering application, differentiation between aortic and peripheral use cases dictates device sizing, delivery-system mechanics, and procedural workflows, which in turn influence clinical training requirements and capital equipment needs. Within device type, the market spans angioplasty balloons-including cutting balloons, drug-coated balloons, and standard balloons-embolic protection devices differentiated by distal or proximal protection, endovascular stent grafts classified into abdominal aortic and thoracic aortic categories, peripheral vascular stents offered as balloon-expandable or self-expanding options, and thrombectomy devices that encompass mechanical and suction thrombectomy approaches. These device-level distinctions drive R&D priorities, regulatory evidence portfolios, and inventory strategies for hospitals and ambulatory settings.

Technology segmentation between bare metal and drug-coated devices further influences clinical pathways and follow-up regimens, as drug-coated platforms aim to reduce restenosis risk and alter reintervention calculus. Implant material choices-cobalt chromium, nitinol, and stainless steel-create performance trade-offs around radial strength, conformability, fatigue resistance, and cost, thereby guiding surgeon selection by lesion type and anatomical demands. End-user segmentation across ambulatory surgery centers, hospitals, and specialty clinics determines procurement cycles, stocking practices, and acceptable device complexity; ambulatory settings typically favor shorter procedure times and simplified inventories, hospitals accommodate more complex cases and higher device diversity, and specialty clinics concentrate on niche procedural volumes and relationship-based purchasing. Mapping strategy to these segmentation axes enables companies and providers to prioritize product portfolios, clinical evidence generation, and commercial models in ways that align with the procedural mix and operational constraints of target end users.

How regional regulatory regimes, reimbursement models, and procedural adoption patterns across the Americas, EMEA, and Asia-Pacific dictate differentiated commercialization and manufacturing choices

Regional dynamics shape innovation pipelines, regulatory strategies, and commercial execution across the aortic and peripheral vascular landscape. In the Americas, clinical adoption is often driven by reimbursement structures that reward procedural efficiency and outcomes, creating a strong environment for technologies that demonstrate reduced length of stay and improved long-term patency. This dynamic encourages manufacturers to invest in robust clinical evidence and to engage early with large integrated delivery networks to secure preferred-supplier status and volume-based arrangements.

Europe, Middle East & Africa present a heterogeneous regulatory and reimbursement environment where national health technology assessment processes and procurement consortia frequently influence device pricing and uptake. Manufacturers operating across this region must adapt to varying evidence requirements and local procurement cycles, while leveraging centralized clinical data to meet diverse national expectations. In contrast, Asia-Pacific is characterized by rapid procedural volume growth, divergent regulatory timelines, and increasing local manufacturing capacity. Market entrants that balance global clinical standards with locally relevant value propositions-including cost-effective implant materials and simplified delivery systems-are often better positioned to scale in high-volume centers while building partnerships with regional distributors and health systems.

Across all regions, cross-border trade policies, reimbursement reform, and the pace of outpatient procedural adoption will continue to shape where and how new devices are launched. Manufacturers should therefore adopt differentiated regional strategies that align clinical evidence packages, pricing models, and supply chain structures with the unique regulatory and provider landscapes of each geography.

An intelligence-driven appraisal of competitive dynamics, innovation vectors, and strategic behaviors that are defining market leadership across device platforms and clinical niches

The competitive landscape in aortic and peripheral vascular devices is marked by a mix of global platform leaders, specialized innovators, and vertically integrated rivals that compete across design, materials, and clinical evidence. Established companies with broad portfolios leverage scale to fund longitudinal clinical trials and to maintain diverse manufacturing footprints, enabling them to offer end-to-end procedural solutions that appeal to large health systems and group purchasing organizations. Specialized companies focus on niche device types-such as drug-coated balloons, advanced stent graft architectures, or thrombectomy system refinements-where clinical differentiation and targeted evidence can accelerate adoption among key opinion leaders.

Strategic behaviors shaping the competitive field include acquisition of complementary technologies to fill gaps in product portfolios, co-development agreements with imaging and guidance system providers to enhance procedural accuracy, and investments in manufacturing capabilities to reduce exposure to tariff and logistics risk. In addition, many market participants are expanding services around device offerings, including training programs, procedural analytics, and warranty or outcome-based contracting mechanisms to strengthen customer relationships. Competitive advantage increasingly arises from the ability to couple compelling device performance with demonstrable operational benefits for providers, backed by high-quality real-world evidence and collaborative commercial models that reduce procurement friction.

Practical, high-impact strategic actions and commercial pivots that manufacturers and providers should implement to secure resilience, accelerate adoption, and demonstrate long-term value

Industry leaders must adopt a suite of tactical and strategic initiatives to sustain growth and respond to a rapidly evolving clinical and commercial environment. Manufacturers should prioritize portfolio rationalization focused on high-impact device families and invest selectively in drug-coating and material science upgrades that offer measurable clinical advantages. Concurrently, strengthening supply chain diversification by qualifying multiple suppliers, pursuing near-shore manufacturing options, and developing modular production capabilities can reduce exposure to trade disruptions and tariff fluctuations.

Commercially, value-based contracting and outcome-linked pricing models merit greater emphasis, with manufacturers developing the capability to present longitudinal clinical and economic evidence that resonates with hospital decision-makers and payers. Investing in data capture and analytics around procedural outcomes will support those contractual conversations and enable continuous performance improvement. Clinician education and streamlined training pathways are also essential; manufacturers should collaborate with leading clinicians to shorten learning curves for newer delivery systems and to codify best practices that improve consistency of outcomes.

Finally, companies should accelerate partnerships with imaging and digital procedural guidance providers to enhance device placement accuracy and to create integrated solutions that improve the overall procedural experience. For providers, adopting inventory rationalization strategies aligned to procedural mix and establishing preferred supplier relationships based on total cost of care metrics will reduce variability and control expenditure. Taken together, these actions will enhance resilience, support adoption of differentiated technologies, and align commercial approaches with evolving stakeholder expectations.

A rigorous mixed-methods research approach combining primary clinical interviews, secondary evidence synthesis, segmentation mapping, and validation procedures to underpin the analysis

The research behind this executive summary relied on a systematic blend of primary and secondary intelligence methodologies to ensure robustness and relevance. Primary research included structured interviews with interventional cardiologists, vascular surgeons, procurement directors, and device engineers to capture firsthand perspectives on clinical utility, device selection criteria, and operational constraints. These interviews were complemented by advisory-panel briefings with device innovators and health system leaders to validate emerging themes and to test commercial scenarios.

Secondary research synthesized peer-reviewed clinical literature, regulatory filings, device labeling, and public financial disclosures to map product attributes, material choices, and approval trajectories. Data triangulation combined qualitative insights with device-specific technical parameters and policy developments, enabling cross-validation of findings and identification of consensus trends. Segmentation mapping was applied to organize insights across application (aortic versus peripheral), device type and subtypes including angioplasty balloons, embolic protection devices, endovascular stent grafts, peripheral stents, and thrombectomy systems, technology differentiation between bare metal and drug-coated platforms, implant materials such as cobalt chromium, nitinol, and stainless steel, and end-user settings spanning ambulatory surgery centers, hospitals, and specialty clinics.

Quality controls included validation of key assertions through multiple independent sources, sensitivity checks on strategic conclusions, and peer review by clinical advisors. Limitations of the methodology were made explicit, particularly where emerging technologies lacked long-term clinical follow-up or where regional regulatory variability constrained direct comparability. Where appropriate, scenario analysis was used to present alternative outcomes rather than single-point predictions, ensuring that stakeholders can apply the research within their own risk and investment frameworks.

A concise synthesis of clinical, commercial, and operational imperatives that stakeholders must align on to navigate dynamic challenges and secure sustainable advances in patient care

In summary, the aortic and peripheral vascular interventional device environment is being redefined by clinical preferences for less invasive, more durable therapies; by material and drug-delivery innovations that alter reintervention risk profiles; and by commercial shifts toward value-based procurement and resilient supply chains. These forces interact across device types-from angioplasty balloons and embolic protection systems to complex stent grafts and thrombectomy platforms-and vary by technology, implant material, and end-user setting. The result is a landscape where technical differentiation must be paired with demonstrable operational and economic value to secure durable adoption.

Stakeholders who align product development with clear clinical endpoints, who invest in supply chain robustness, and who embrace outcome-linked commercial models will be best positioned to capture long-term value. Regulators and payers will continue to place a premium on high-quality evidence and real-world performance data, making longitudinal outcome measurement a central component of successful market entry. By integrating clinical, commercial, and operational strategies, manufacturers and providers can navigate tariff volatility, regional variation, and evolving procedural practice to deliver improved patient outcomes while managing institutional cost pressures.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Aortic & Peripheral Vascular Interventional Devices Market, by Device Type

  • 8.1. Angioplasty Balloons
    • 8.1.1. Cutting Balloons
    • 8.1.2. Drug-Coated Balloons
    • 8.1.3. Standard Balloons
  • 8.2. Embolic Protection Devices
    • 8.2.1. Distal Protection
    • 8.2.2. Proximal Protection
  • 8.3. Endovascular Stent Grafts
    • 8.3.1. Abdominal Aortic
    • 8.3.2. Thoracic Aortic
  • 8.4. Peripheral Vascular Stents
    • 8.4.1. Balloon-Expandable
    • 8.4.2. Self-Expanding
  • 8.5. Thrombectomy Devices
    • 8.5.1. Mechanical Thrombectomy
    • 8.5.2. Suction Thrombectomy

9. Aortic & Peripheral Vascular Interventional Devices Market, by Technology

  • 9.1. Bare Metal
  • 9.2. Drug-Coated

10. Aortic & Peripheral Vascular Interventional Devices Market, by Implant Material

  • 10.1. Cobalt Chromium
  • 10.2. Nitinol
  • 10.3. Stainless Steel

11. Aortic & Peripheral Vascular Interventional Devices Market, by Application

  • 11.1. Aortic
  • 11.2. Peripheral

12. Aortic & Peripheral Vascular Interventional Devices Market, by End User

  • 12.1. Ambulatory Surgery Centers
  • 12.2. Hospitals
  • 12.3. Specialty Clinics

13. Aortic & Peripheral Vascular Interventional Devices Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Aortic & Peripheral Vascular Interventional Devices Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Aortic & Peripheral Vascular Interventional Devices Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Aortic & Peripheral Vascular Interventional Devices Market

17. China Aortic & Peripheral Vascular Interventional Devices Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. B. Braun Melsungen AG
  • 18.7. Becton, Dickinson and Company
  • 18.8. Boston Scientific Corporation
  • 18.9. Cardinal Health
  • 18.10. Cook Medical LLC
  • 18.11. Getinge AB
  • 18.12. Johnson & Johnson
  • 18.13. LivaNova PLC
  • 18.14. Medtronic plc
  • 18.15. Merit Medical Systems, Inc.
  • 18.16. MicroPort Endovascular MedTech
  • 18.17. Penumbra, Inc.
  • 18.18. Terumo Corporation
  • 18.19. W. L. Gore & Associates, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY CUTTING BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY CUTTING BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY CUTTING BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG-COATED BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG-COATED BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG-COATED BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY STANDARD BALLOONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY STANDARD BALLOONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY STANDARD BALLOONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DISTAL PROTECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DISTAL PROTECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DISTAL PROTECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PROXIMAL PROTECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PROXIMAL PROTECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PROXIMAL PROTECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ABDOMINAL AORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ABDOMINAL AORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ABDOMINAL AORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THORACIC AORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THORACIC AORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THORACIC AORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY BALLOON-EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SELF-EXPANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SELF-EXPANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SELF-EXPANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY MECHANICAL THROMBECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SUCTION THROMBECTOMY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SUCTION THROMBECTOMY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SUCTION THROMBECTOMY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY BARE METAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY BARE METAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY BARE METAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG-COATED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG-COATED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DRUG-COATED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COBALT CHROMIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COBALT CHROMIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COBALT CHROMIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY NITINOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY NITINOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY NITINOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY AORTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY AORTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY AORTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 149. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 150. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 151. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 160. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 161. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 162. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 163. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 171. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 172. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 173. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 174. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 175. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. GLOBAL AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 192. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 194. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 195. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 198. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 199. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 200. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 201. GCC AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPEAN UNION AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 216. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 217. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 218. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 219. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 220. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 222. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 223. BRICS AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 224. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 225. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 227. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 228. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 229. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 230. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 231. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 233. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. G7 AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 235. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 236. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ANGIOPLASTY BALLOONS, 2018-2032 (USD MILLION)
  • TABLE 238. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY EMBOLIC PROTECTION DEVICES, 2018-2032 (USD MILLION)
  • TABLE 239. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY ENDOVASCULAR STENT GRAFTS, 2018-2032 (USD MILLION)
  • TABLE 240. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY PERIPHERAL VASCULAR STENTS, 2018-2032 (USD MILLION)
  • TABLE 241. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY THROMBECTOMY DEVICES, 2018-2032 (USD MILLION)
  • TABLE 242. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 243. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY IMPLANT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 244. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 245. NATO AORTIC & PERIPHERAL VASCULAR INTERVENTIONAL DEVICES MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. GLOBAL AORTIC & PERIPHERAL VASCULAR INTER